Ligandrol (LGD-4033) ZPHC — 10 mg

Overview of Ligandrol (LGD-4033)

Ligandrol, commonly identified as LGD-4033, is a synthetic selective androgen receptor modulator (SARM) that has been investigated for its interaction with androgen receptors. The compound is also known as VK-5211 or Anabolicum. The listed ZPHC product is described as containing 10 mg tablets in a 100-tablet package, although the contents, purity, and quality of any particular commercial product should be independently verified.

LGD-4033 has attracted research interest because SARMs were developed to investigate selective activity at androgen receptors. Unlike conventional anabolic-androgenic steroids, SARMs were designed to interact with androgen receptors in a more tissue-selective manner. However, selective receptor activity does not mean that a compound is risk-free or approved for human use.

The U.S. Food and Drug Administration specifically identifies LGD-4033 as a SARM and states that SARMs are not FDA-approved. The FDA has also reported serious adverse events associated with SARMs, including liver injury, and warns of potential cardiovascular risks.

LGD-4033 and Research Interest

LGD-4033 is primarily discussed in scientific and research contexts because of its ability to interact with androgen receptors. Researchers studying androgen-receptor signaling may examine compounds such as LGD-4033 to better understand receptor activation, anabolic signaling, and related biological pathways.

It is important to distinguish research interest from established medical use. LGD-4033 is not an FDA-approved medication, and the FDA states that SARMs cannot legally be marketed in the United States as dietary supplements or approved drugs.

This distinction is particularly important when evaluating online product descriptions. Marketing language may present SARMs as straightforward muscle-building or performance products, but such claims should not be interpreted as evidence of established safety or effectiveness.

Product Specifications

The listed product configuration is:

• Product: Ligandrol (LGD-4033) ZPHC
• Strength listed: 10 mg per tablet
• Quantity: 100 tablets
• Total labeled amount: 1,000 mg
• Compound name: LGD-4033
• Alternative name: Ligandrol
• Compound class: SARM
• Intended context: Research

A product listing should always be evaluated according to its actual labeling, documentation, batch information, and applicable regulations. A product name or stated concentration alone does not establish purity, authenticity, sterility, safety, or regulatory approval.

Important Safety Information

The safety profile of LGD-4033 deserves careful consideration. The FDA warns that SARMs are potentially dangerous and have been associated with serious or life-threatening health problems. Reported concerns include liver injury or acute liver failure, increased risk of heart attack or stroke, sexual dysfunction, infertility, sleep disturbances, and other adverse effects.

The FDA has also taken enforcement action against businesses marketing LGD-4033 and other SARMs as products for human use. In a December 2025 warning letter, the agency identified LGD-4033/Ligandrol among SARM products being marketed in the United States as unapproved new drugs.

For that reason, claims suggesting that LGD-4033 is a guaranteed solution for muscle growth, strength, fat loss, recovery, or athletic performance should be treated cautiously.

Regulatory Considerations in the USA

For customers researching ZPHC LGD-4033 in the United States, regulatory status is an important consideration. The FDA states that SARMs are not approved for use as dietary supplements or drugs and recommends that consumers avoid products marketed as SARMs for muscle-building or performance-enhancing purposes.

This means that an online listing should not be interpreted as evidence that a product has been reviewed or approved by the FDA.

LGD-4033 also has implications for competitive athletes. The World Anti-Doping Agency’s prohibited list identifies LGD-4033 (Ligandrol) as a prohibited selective androgen receptor modulator under the anabolic agents category.

Athletes subject to anti-doping rules should therefore check the current rules applicable to their sport and governing organization before exposure to any prohibited substance.

Why Product Verification Matters

Online research-compound markets can contain products with varying levels of documentation and quality control. Product packaging, claimed dosage, and brand names should not automatically be considered proof of laboratory purity.

When evaluating a product such as Ligandrol LGD-4033, useful documentation may include:

• Batch or lot identification
• Certificate of analysis from an appropriately qualified laboratory
• Independent analytical testing
• Ingredient identity and concentration
• Manufacturer information
• Storage information
• Applicable regulatory disclosures

Consumers should be particularly cautious when websites make unusually strong promises about rapid physical transformation or guaranteed performance outcomes. The FDA specifically warns that SARMs are sometimes promoted online as quick or easy ways to improve appearance, gain muscle, or enhance athletic performance despite their lack of FDA approval.

A Research-Focused Perspective on LGD-4033

From an SEO and educational perspective, Ligandrol LGD-4033 is a relevant search term for readers researching SARMs, androgen-receptor compounds, and experimental anabolic agents.

However, responsible product information should clearly separate established scientific facts from promotional claims. LGD-4033 has been investigated because of its activity at androgen receptors, but that research history should not be interpreted as proof that the compound is safe or appropriate for self-administration.

The strongest product information is transparent about what is known, what remains uncertain, and what regulatory restrictions apply. This approach is particularly important for U.S. audiences searching for ZPHC LGD-4033, Ligandrol 10 mg, LGD-4033 10 mg tablets, or related terms.

Frequently Asked Questions

What is LGD-4033?

LGD-4033, commonly called Ligandrol, is a synthetic selective androgen receptor modulator. It has been investigated for its interaction with androgen receptors.

Is LGD-4033 FDA approved?

No. The FDA states that SARMs, including LGD-4033, are not FDA-approved and cannot legally be marketed in the United States as dietary supplements or approved drugs.

What does the listed ZPHC package contain?

The product specification provided for this listing is 100 tablets at 10 mg per tablet, for a stated total of 1,000 mg.

Is Ligandrol prohibited for athletes?

LGD-4033 is listed by WADA among prohibited SARMs under the anabolic agents category.

Are SARMs risk-free because they are selective?

No. Selective receptor activity does not establish safety. FDA warnings describe potentially serious risks associated with SARMs, including liver injury and cardiovascular events.

Final Product Perspective

Ligandrol (LGD-4033) ZPHC — 10 mg, 100 tablets is a product listing associated with a compound that has generated significant scientific and bodybuilding-community interest. Nevertheless, its status as a SARM and its lack of FDA approval are important considerations for anyone researching the product in the United States.

Rather than relying on aggressive marketing claims, buyers and researchers should examine independent documentation, regulatory information, and the known safety concerns surrounding LGD-4033. This provides a more powerful, transparent, and responsible basis for evaluating information about the compound.

This description is provided for informational and research purposes and is not medical advice or a recommendation to use LGD-4033. Anyone concerned about exposure to a SARM or experiencing possible adverse effects should consult an appropriately qualified healthcare professional.